WR 279,396 for the Treatment of Cutaneous Leishmaniasis
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The objectives of the study are to evaluate the safety and efficacy of open label treatment
with WR 279,396 (topical paromomycin & gentamicin) in patients with non-complicated,
non-severe cutaneous leishmaniasis (CL).
Phase:
Phase 2
Details
Lead Sponsor:
Assistance Publique - Hôpitaux de Paris
Collaborators:
U.S. Army Medical Research and Development Command U.S. Army Medical Research and Materiel Command